Cover Image

IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy

Myeloid-derived suppressor cells (MDSC) are generated during tumor progression and suppress the anti-tumor functions of T and natural killer (NK) cells. Their enrichment is associated with a bad prognosis and a worse outcome of immunotherapy in cancer patients. The cytokine interleukin (IL)-6 was fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Bitsch, Rebekka (Author) , Groth, Christopher (Author) , Lasser, Samantha (Author) , Arkhypov, Ihor (Author) , Petrova, Vera (Author) , Altevogt, Peter (Author) , Utikal, Jochen (Author) , Umansky, Viktor (Author)
Format: Article (Journal)
Language:English
Published: January 2021
In: Cellular immunology
Year: 2021, Volume: 359, Pages: 1-8
ISSN:1090-2163
DOI:10.1016/j.cellimm.2020.104254
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.cellimm.2020.104254
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0008874920304147
Get full text
Author Notes:Rebekka Weber, Christopher Groth, Samantha Lasser, Ihor Arkhypov, Vera Petrova, Peter Altevogt, Jochen Utikal, Viktor Umansky
Description
Summary:Myeloid-derived suppressor cells (MDSC) are generated during tumor progression and suppress the anti-tumor functions of T and natural killer (NK) cells. Their enrichment is associated with a bad prognosis and a worse outcome of immunotherapy in cancer patients. The cytokine interleukin (IL)-6 was found to be a crucial regulator of MDSC accumulation and activation as well as a factor, stimulating tumor cell proliferation, survival, invasiveness and metastasis. Accordingly, IL-6 can serve as a negative prognostic marker in cancer. On the other hand, this cytokine is also involved in T cell activation. This review discusses the pleiotropic effects of IL-6 on immune cell populations that are critical for tumor development, such as MDSC and T cells, and summarizes the data on targeting IL-6 or IL-6 receptor (IL-6R) for tumor immunotherapy to block MDSC-mediated immunosuppression in cancer patients.
Item Description:Available online 29 November 2020
Gesehen am 08.02.2021
Physical Description:Online Resource
ISSN:1090-2163
DOI:10.1016/j.cellimm.2020.104254

Similar Items